News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
557,561 Results
Type
Article (45097)
Company Profile (135)
Press Release (512329)
Section
Business (155144)
Career Advice (2399)
Deals (28996)
Drug Delivery (113)
Drug Development (71107)
Employer Resources (148)
FDA (15758)
Job Trends (12436)
News (278376)
Policy (30452)
Tag
Academia (2348)
Alliances (36858)
Alzheimer's disease (1356)
Antibody-drug conjugate (ADC) (106)
Approvals (15686)
Artificial intelligence (156)
Bankruptcy (309)
Best Places to Work (9636)
Breast cancer (197)
Cancer (1482)
Cardiovascular disease (129)
Career advice (2000)
CAR-T (106)
Cell therapy (311)
Clinical research (56947)
Collaboration (502)
Compensation (307)
COVID-19 (2606)
C-suite (125)
Data (1391)
Diabetes (191)
Diagnostics (5356)
Drug pricing (109)
Earnings (64824)
Employer resources (136)
Events (89826)
Executive appointments (448)
FDA (16524)
Funding (451)
Gene therapy (226)
GLP-1 (702)
Government (4053)
Healthcare (15539)
Infectious disease (2705)
Inflammatory bowel disease (110)
Interviews (446)
IPO (14452)
Job creations (3195)
Job search strategy (1667)
Layoffs (463)
Legal (7137)
Lung cancer (222)
Manufacturing (208)
Medical device (11476)
Medtech (11479)
Mergers & acquisitions (14785)
Metabolic disorders (541)
Neuroscience (1728)
NextGen: Class of 2025 (5196)
Non-profit (3368)
Northern California (1757)
Obesity (317)
Opinion (202)
Patents (132)
People (43642)
Phase I (16875)
Phase II (24758)
Phase III (20163)
Pipeline (619)
Postmarket research (2375)
Preclinical (6958)
Radiopharmaceuticals (215)
Rare diseases (299)
Real estate (4396)
Regulatory (20906)
Research institute (2094)
Resumes & cover letters (402)
Southern California (1494)
Startups (2814)
United States (15128)
Vaccines (651)
Weight loss (248)
Date
Today (152)
Last 7 days (381)
Last 30 days (1866)
Last 365 days (32030)
2025 (1726)
2024 (32384)
2023 (36363)
2022 (46519)
2021 (50205)
2020 (47192)
2019 (38128)
2018 (28868)
2017 (28815)
2016 (27345)
2015 (30614)
2014 (24111)
2013 (19571)
2012 (21040)
2011 (21510)
2010 (19456)
Location
Africa (678)
Arizona (156)
Asia (32020)
Australia (5589)
California (3914)
Canada (1245)
China (301)
Colorado (176)
Connecticut (202)
Europe (77426)
Florida (563)
Georgia (133)
Illinois (348)
Indiana (203)
Maryland (649)
Massachusetts (3037)
Michigan (152)
Minnesota (277)
New Jersey (1107)
New York (1089)
North Carolina (746)
Northern California (1757)
Ohio (128)
Pennsylvania (895)
South America (1045)
Southern California (1494)
Texas (548)
Washington State (394)
557,561 Results for "kedrion s p a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Kedrion Selected by Biotest to Distribute its Immunoglobulin Yimmugo® in the U.S. Following Recent FDA Approval
Kedrion Biopharma Inc. announced that it has established the framework for a long-term agreement with Biotest AG for the full commercialization and distribution of the immunoglobulin therapy Yimmugo® in the U.S., following its Biologic License Application approval by the U.S. Food and Drug Administration on June 13, 2024.
July 1, 2024
·
5 min read
Pharm Country
Kedrion Announces Rare Disease Medicine RYPLAZIM® Now Available in US
Kedrion Biopharma Inc. announced today that plasminogen deficiency type 1 (PLGD-1) patients in the U.S. now have access to RYPLAZIM® (plasminogen, human-tvmh).
April 29, 2024
·
5 min read
Press Releases
FDA Approves Kedrion’s Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim®
November 21, 2024
·
2 min read
Press Releases
Kedrion and Biotest complete long-term Exclusive Distribution Agreement for Yimmugo® in the US
October 2, 2024
·
5 min read
Press Releases
Kedrion Biopharma’s Focus on Advancing Patient Care in Rare Disease to be Showcased at NBDF Conference 2024
September 12, 2024
·
3 min read
Business
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
Kamada Ltd. announced the execution of a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB® U.S. distribution agreement between the parties.
December 6, 2023
·
8 min read
Kedrion Announces an Eight-Year Extension of the Distribution Agreement With Kamada in the US for KEDRAB®
Kedrion Biopharma announces the execution of a binding memorandum of understanding with Kamada Ltd., an Israeli commercial stage global biopharmaceutical company and leader in the specialty plasma-derived field, for the amendment and the 8-year extension of the KEDRAB® US distribution agreement between the two companies.
December 7, 2023
·
5 min read
Press Releases
David P. King Joins Truvian’s Advisory Board
January 13, 2025
·
2 min read
Pharm Country
Kedrion Biopharma Marks Fourth Annual Hereditary Factor 10 Deficiency Day on October 10
Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, is proud to recognize the fourth Hereditary Factor X Deficiency Awareness Day on October 10, 2023.
October 10, 2023
·
2 min read
Pharm Country
Kedrion’s global portfolio expands to China to supply human Albumin
Kedrion Biopharma has announced that China’s National Institutes for Food and Drug Control has approved BPL’s human Albumin product for release to the Chinese market.
July 12, 2023
·
3 min read
1 of 55,757
Next
